JP2012532879A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532879A5
JP2012532879A5 JP2012519703A JP2012519703A JP2012532879A5 JP 2012532879 A5 JP2012532879 A5 JP 2012532879A5 JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012532879 A5 JP2012532879 A5 JP 2012532879A5
Authority
JP
Japan
Prior art keywords
cancer
itpp
effective amount
therapeutically effective
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012519703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532879A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041250 external-priority patent/WO2011005886A1/en
Publication of JP2012532879A publication Critical patent/JP2012532879A/ja
Publication of JP2012532879A5 publication Critical patent/JP2012532879A5/ja
Pending legal-status Critical Current

Links

JP2012519703A 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法 Pending JP2012532879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22358309P 2009-07-07 2009-07-07
US61/223,583 2009-07-07
PCT/US2010/041250 WO2011005886A1 (en) 2009-07-07 2010-07-07 Method of reducing multi-drug resistance using inositol tripyrophosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015127462A Division JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Publications (2)

Publication Number Publication Date
JP2012532879A JP2012532879A (ja) 2012-12-20
JP2012532879A5 true JP2012532879A5 (enExample) 2013-08-29

Family

ID=43429524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012519703A Pending JP2012532879A (ja) 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Country Status (7)

Country Link
US (3) US20120003327A1 (enExample)
EP (1) EP2451459B1 (enExample)
JP (2) JP2012532879A (enExample)
CN (2) CN103495170A (enExample)
MX (1) MX2012000383A (enExample)
RU (1) RU2563127C2 (enExample)
WO (1) WO2011005886A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
JP6956091B2 (ja) 2016-08-26 2021-10-27 哲治 奥野 微小ナノ化薬剤およびその利用
JP2019535651A (ja) * 2016-10-04 2019-12-12 アスクレピクス セラピューティクス インコーポレイテッド Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法
MA51276A (fr) * 2017-12-22 2021-04-21 Lo Li Pharma Srl Traitement de la fibrose avec de l'inositol
WO2019213462A1 (en) * 2018-05-03 2019-11-07 Normoxys, Inc. Inositol-based immunotherapies
TWI686210B (zh) 2018-06-01 2020-03-01 國立清華大學 用以誘導病變組織血管正常化的套組及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
US6632797B2 (en) * 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
JP3989997B2 (ja) * 1997-04-08 2007-10-10 ポーラ化成工業株式会社 放射線増感剤の製造方法
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
ES2237447T3 (es) * 1999-09-13 2005-08-01 Pola Chemical Industries, Inc. Derivado de nitroimidazol y agente de diagnostico formador de imagenes que lo contiene.
US7084115B2 (en) * 2002-04-29 2006-08-01 Oxyplus, Inc. Inositol pyrophosphates, and methods of use thereof
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
WO2006102060A1 (en) * 2005-03-18 2006-09-28 Oxyplus, Inc. Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
AU2006335318A1 (en) * 2006-01-06 2007-07-19 Oxyplus, Inc. Use of inositol-tripyrophosphate in treating tumors and diseases

Similar Documents

Publication Publication Date Title
JP2012532879A5 (enExample)
Yan et al. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction
Sarkar et al. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells
Bhanumathi et al. Drug-carrying capacity and anticancer effect of the folic acid-and berberine-loaded silver nanomaterial to regulate the AKT-ERK pathway in breast cancer
Sharma et al. A marine sponge alkaloid derivative 4-chloro fascaplysin inhibits tumor growth and VEGF mediated angiogenesis by disrupting PI3K/Akt/mTOR signaling cascade
Wang et al. Novel antitumor agent, trilacunary keggin-type tungstobismuthate, inhibits proliferation and induces apoptosis in human gastric cancer SGC-7901 cells
Wang et al. Specific cell targeting with APRPG conjugated PEG–PLGA nanoparticles for treating ovarian cancer
Aguilar-Gallardo et al. Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches
RU2018105985A (ru) Новый подход к лечению рака с применением иммуномодуляции
Yang et al. Responsively aggregatable sub-6 nm nanochelators induce simultaneous antiangiogenesis and vascular obstruction for enhanced tumor vasculature targeted therapy
Manatunga et al. Effective delivery of hydrophobic drugs to breast and liver cancer cells using a hybrid inorganic nanocarrier: a detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry
Zhong et al. Targeting proinflammatory molecules using multifunctional MnO nanoparticles to inhibit breast cancer recurrence and metastasis
CN107921047B (zh) 芳基喹啉衍生物作为血管生成拟态抑制剂的新用途
JP2007519609A5 (enExample)
Pandey et al. Prooxidative activity of plumbagin induces apoptosis in human pancreatic ductal adenocarcinoma cells via intrinsic apoptotic pathway
RU2012104022A (ru) Способ уменьшения мультилекарственной резистентности с использованием трипирофосфата инозита
Das et al. Recent trends in the design and delivery strategies of ruthenium complexes for breast cancer therapy
AU2014219129A1 (en) Caged platinum nanoclusters for anticancer chemotherapeutics
Chen et al. Multifunctional microspheres dual-loaded with doxorubicin and sodium bicarbonate nanoparticles to introduce synergistic trimodal interventional therapy
Patwekar et al. Mechanistic insights on anticancer drugs with specific biological targets and signalling pathways
CN106459011A (zh) 作为抗肿瘤化合物的σ‑2受体配体药物缀合物、其合成方法及其用途
JP2017509672A5 (enExample)
Shao et al. Strategies of porous network quinolone polymers: A comprehensive evaluation of their biological activity
Manatunga et al. Effective delivery of hydrophobic drugs to breast (MCF-7) and Liver (HepG2) cancer cells: A detailed investigation using Cytotoxicity assays, fluorescence imaging and flow cytometry
Fu et al. A review: advances of curcumin co-delivery biomaterials-based system in anti-tumor therapy